Efficacy of antiplatelets in deep venous thrombosis
Venous thromboembolism (VTE) is the third most common cardiovascular disease in the world. Every year, 30,000 people in Australia develop VTE, at a cost of $1.72 billion to the Australian health system.
The impact of air pollution
Air pollution is making us sick according to local and global research, including a study linking exposure to air pollution with subsequent acute cardiac...
Inside a multidisciplinary antenatal vaccination clinic
To protect pregnant women and their unborn babies from the severe adverse outcomes associated with the virus, the first pharmacist-led COVID-19 vaccination clinic for pregnant women opened in Western Australia’s King Edward Memorial Hospital on 20 September.
Lack of evidence raises questions on long-term PPI use
There is rising concern over the side effects of long-term proton pump inhibitor (PPI) use but limited evidence to warrant discontinuation, a literature review...
Pharmacy Board’s measured step on prescribing
The Pharmacy Board of Australia has recognised that pharmacists should be able to prescribe under two monitored models of prescribing, in a move welcomed...
Quick Q&A with Katherine Higgins MPS
Jennifer Cooke, the Editor of Australian Pharmacist, talks with Katherine Higgins, a pharmacist in South Perth, Western Australia.












